Securities code: 002900 securities abbreviation: Harbin Medisan Pharmaceutical Co.Ltd(002900) Announcement No.: 2022-007 Harbin Medisan Pharmaceutical Co.Ltd(002900)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance:
(1) Performance forecast from January to December 2021 \uf0f0 turning loss into profit √ rising in the same direction \uf0f0 declining in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 349 million yuan – 379 million yuan
Net profit of shareholders: 29.3248 million yuan, an increase of 1090.12% – 1192.42% over the same period of last year
Deducting non recurring losses: 151 million yuan – 121 million yuan
The net profit after profit decreased by 613.73% – 471.93% compared with the same period of the previous year, and the loss was 21.1563 million yuan
Basic earnings per share: 1.13 yuan / share – 1.22 yuan / share earnings: 0.09 yuan / share
Note: “Yuan” refers to RMB
2、 Communication with accounting firms
The relevant data of this performance forecast is the preliminary calculation result of the company’s financial department and has not been audited by an accounting firm. However, the company has conducted pre communication with the annual report audit accounting firm on matters related to the performance forecast, and there is no significant difference between the company and the accounting firm in the performance forecast of the reporting period.
3、 Explanation of performance change reasons
(1) The company’s net profit attributable to shareholders of Listed Companies in 2021 increased year-on-year, mainly due to the impact of non recurring profits and losses. The company held the 9th meeting of the 3rd board of directors and the 7th Meeting of the 3rd board of supervisors on February 9, 2021, deliberated and adopted the proposal on foreign investment with equity of wholly-owned subsidiaries, and deliberated and adopted the proposal on foreign investment with equity of wholly-owned subsidiaries at the 2nd extraordinary general meeting of shareholders in 2021, In 2021, the company increased the capital of Harbin fuerjia Technology Development Co., Ltd. with 100% equity of Harbin Beixing Pharmaceutical Co., Ltd. The transaction price takes December 31, 2020 as the appraisal base date. According to the appraisal results and confirmed by both parties, the 100% equity value of Beixing pharmaceutical is 570 million yuan.
The initial investment cost of the company to Harbin Beixing Pharmaceutical Co., Ltd. was 3.51 million yuan, resulting in an investment income of about 566.49 million yuan. The total profit affected by the transaction on the level of the company’s consolidated statements in 2021 was about 566.49 million yuan. After confirming the corresponding income tax expenses, the net profit affected by the level of the consolidated statements in 2021 was about 481.5165 million yuan. The specific amount shall be confirmed after being audited by the annual auditor.
(2) After Beixing Pharmaceutical Co., Ltd. invested abroad, it stripped off its original medical device and cosmetics production business and was no longer included in the scope of company merger. At the same time, the pharmaceutical sector of the company has been greatly impacted by the national key monitoring catalogue policy of rational drug use and covid-19 epidemic, and the sales volume of some products has declined. Two factors led to a year-on-year decrease of about 30.00% in operating income. The fixed costs such as wages, depreciation and amortization are relatively stable, the expenses during sales, management and R & D decreased by only about 10.00% year-on-year, and the operating revenue can not fully cover the operating costs and period expenses, resulting in a negative net profit after deducting non recurring profits and losses;
(3) According to the principle of prudence, the company accrued asset impairment for various assets at the end of the period. The asset impairment loss of this year is expected to be 13.4451 million yuan, including 3.0144 million yuan of inventory falling price reserve for inventory and 10.4307 million yuan of long-term equity investment impairment reserve for Heilongjiang weikai’er Biotechnology Co., Ltd., which belongs to recurring profit and loss.
4、 Other relevant instructions
This performance forecast is the result of the preliminary calculation of the company’s financial department and needs to be audited by an accounting firm. The specific financial data will be disclosed in detail in the company’s 2021 annual report. Please pay attention to the investment risks.
It is hereby announced.
Harbin Medisan Pharmaceutical Co.Ltd(002900) board of directors January 28, 2022
